| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:4219-4225.)
© 1997 American Heart Association, Inc.
Articles |
Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases
The Atherosclerosis Risk In Communities (ARIC) Study
From the Human Genetics Center (S.-J.H., E.B.) and Institute of Molecular Medicine (E.B.), University of Texas–Houston Health Science Center; the Department of Medicine, Baylor College of Medicine (C.M.B., L.C.S., A.M.G.), Houston, Tex; the Epidemiology and Biometry Program, National Heart, Lung, and Blood Institute, Bethesda, Md (A.R.S.); and the Department of Biostatistics, University of North Carolina School of Public Health, Chapel Hill (C.E.D.).
Correspondence to Eric Boerwinkle, PhD, Human Genetics Center, PO Box 20334, Houston, TX 77225. E-mail eboerwin{at}gsbs.uth.tmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background Recruitment of circulating leukocytes at sites of atherosclerosis is mediated through a family of adhesion molecules. The function of circulating forms of these adhesion molecules remains unknown, but their levels may serve as molecular markers of subclinical coronary heart disease (CHD).
Methods and Results To determine the ability of circulating vascular cell adhesion molecule-1 (VCAM-1), endothelial-leukocyte adhesion molecule-1 (E-selectin), and intercellular adhesion molecule-1 (ICAM-1) to serve as molecular markers of atherosclerosis and predictors of incident CHD, we studied 204 patients with incident CHD, 272 patients with carotid artery atherosclerosis (CAA), and 316 control subjects from the large, biracial Atherosclerosis Risk In Communities (ARIC) study. Levels of VCAM-1 were not significantly different among the patients with incident CHD, those with CAA, and control subjects. Higher levels of E-selectin and ICAM-1 were observed for the patients with CHD (means [ng/mL]: E-selectin, 38.4; ICAM-1, 288.7) and those with CAA (E-selectin, 41.5; ICAM-1, 283.6) compared with the control subjects (E-selectin, 32.8; ICAM-1, 244.2), but the distributions were not notably different between the patients with CHD and CAA. Results of logistic regression analyses indicated that the relationship of ICAM-1 and E-selectin with CHD and CAA was independent of other known CHD risk factors and was most pronounced in the highest quartile. The odds of CHD and CAA were 5.53 (95% CI, 2.51–12.21) and 2.64 (95% CI, 1.40–5.01), respectively, for those with levels of ICAM-1 in the highest quartile compared with those in the lowest quartile. Odds of CAA were 2.03 (95% CI, 1.14–3.62) for those with levels of E-selectin in the highest quartile compared with those in the lowest quartile.
Conclusions These data indicate that plasma levels of ICAM-1 and E-selectin may serve as molecular markers for atherosclerosis and the development of CHD.
Key Words: atherosclerosis • coronary heart disease • adhesion molecules
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Atherosclerosis and its clinical sequelae remain the leading causes of morbidity and mortality in both men and women of all racial groups in the United States and most westernized societies.1 Development of atherosclerosis is characterized by a steady accumulation of inflammatory molecules, complex lipids, and fibrin sometimes culminating in clinically recognized events (ie, CHD).2–6 Accumulated evidence indicates that a majority of clinical events result from mild to modest coronary lesions that abruptly progress to severe obstructions.7 Lesions prone to plaque disruption are those with a large core lipid pool and a structurally weakened fibrous cap.8 Lipid-lowering therapy has proved to be efficient in deterring plaque progression.9 However, the cost-effectiveness of lipid-lowering therapy varies with CHD risk factors and duration of intervention.10 Early detection programs rely on diagnostic techniques such as ultrafast CT scans11 and positron emission tomography or coronary angiography, which are expensive and cannot be easily offered in all practice settings.12 Advances in our knowledge of the molecular basis of atherosclerosis make possible the development of molecular markers that can be measured in plasma or serum and used for the identification of individuals at high risk of CHD.13
Binding and recruitment of circulating leukocytes to the vascular endothelium and further migration into the subendothelial spaces are major processes in the development of atherosclerosis and are mediated through a diverse family of cellular adhesion molecules that are expressed on the surface of vascular endothelial cells.14 Among the identified adhesion molecules, the expression and biological properties of VCAM-1, endothelial-leukocyte adhesion molecule-1 (E-selectin), and ICAM-1 are well characterized.15–22 The accumulated data imply that selectins mediate initial rolling of leukocytes along the endothelium and that VCAM-1 and ICAM-1 play important roles in the firm attachment and transendothelial migration of leukocytes. These molecules have been observed consistently within the milieu of the atherosclerotic plaque. Results of immunohistochemical studies show different levels of expression of these molecules that reflect their unique structural and functional characteristics.23–28 Circulating forms of VCAM-1, E-selectin, and ICAM-1 have been detected in plasma and are elevated during inflammatory conditions in which detailed pathology studies have documented increased expression of cellular adhesion molecules on endothelial cells and other tissue types.15,29,30 The origins of circulating VCAM-1, E-selectin, and ICAM-1 are unclear, but they may arise from shedding or proteolytic cleavage from endothelial cells.31,32 The present study is based on the hypothesis that circulating levels of VCAM-1, E-selectin, and ICAM-1 may be useful markers for increased expression of cellular adhesion molecules in atherosclerosis. To test the hypothesis, we examined the relationship between levels of circulating VCAM-1, E-selectin, ICAM-1, and the extent of atherosclerosis as identified by B-mode ultrasound. We also tested whether the levels of circulating adhesion molecules predict the risk of incident CHD in the ARIC study, in which the CHD patients were identified during a 5-year follow-up period.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The sample for this investigation was selected from the large, biracial ARIC study. This cohort study was designed to investigate the causes of atherosclerosis and its clinical sequelae and variation in cardiovascular risk factors. The study population consisted of 15 792 adults 45 to 64 years old in four US communities: Forsyth County, North Carolina; Jackson, Miss; the northwestern suburbs of Minneapolis, Minn; and Washington County, Maryland. All subjects in Jackson and 12% of those in Forsyth County were black; most others were white. A complete description of the design, objectives, sampling strategies, and examination techniques of the ARIC study was published previously.33 For this analysis, three groups were defined: patients with incident CHD, those with CAA, and control subjects. The CHD cases consisted of patients with fatal and nonfatal events, including surgical revascularization procedures and undiagnosed myocardial infarction, that were identified after the first examination of the cohort (November 1986 to November 1989) and who had complete data as of July 1994. The criteria for fatal CHD were based on chest pain, the underlying cause of death from the death certificate, and other medical information. The criteria for nonfatal CHD events were based on combinations of chest pain symptoms, ECG changes, cardiac enzyme levels, and surgical revascularization procedures. All potential CHD events were reviewed by two members of the ARIC Morbidity and Mortality Classification Committee, and differences between the two reviewers were adjudicated by the chairperson of the committee. Carotid artery wall thickness was measured by a bilateral high-resolution B-mode ultrasound examination of the extracranial carotid arteries at three segments (the distal section of the common, the bifurcation, and the proximal portion of the internal carotid arteries).34 CAA patients are ARIC participants having a minimum average intima-media far-wall thickness >1.0 mm at visits 1 and 2. The control subjects were identified as having an average intima-media far-wall thickness <0.68 mm at visits 1 and 2. These intima-media thickness cutpoints correspond approximately to the 95th and 30th percentiles, respectively, of the ARIC cohort. One or two control subjects were randomly selected for each CAA case within relevant sex and age (<55 years,
55 years) strata. These ultrasound-defined patients and
control subjects could not have symptomatic
cardiovascular or cerebrovascular disease at visit 1 or
2, and they could not have already been identified as incident CHD
patients. Exclusion criteria included reported prevalent
coronary heart disease at visit 1, a <12-hour fast before the
examination, and races other than black or white.
Blood samples and the data presented here were collected at the
baseline examinations. Levels of plasma lipids and hemostatic factors
were measured in centralized laboratories by standard and validated
methods reported previously.35–37 Information
about medical history, cigarette smoking, and ethanol consumption was
elicited from standardized and validated interviewer-administered
questionnaires. Prevalent hypertension was defined as a
systolic blood pressure 160 mm Hg, a
diastolic blood pressure 95 mm Hg, or current use
of antihypertensive medications. Prevalent diabetes mellitus was
defined as a fasting glucose level 140 mg/dL, nonfasting glucose
200 mg/dL, or a history of or treatment for diabetes. Circulating
VCAM-1, E-selectin, and ICAM-1 levels were determined by commercially
available ELISA and standards (R&D System Europe Ltd). Those who had
extreme values of VCAM-1, E-selectin, or ICAM-1 (mean±3 SD) were
deleted from analyses for that adhesion molecule (n=13, 8, and
6 for VCAM-1, E-selectin, and ICAM-1, respectively).
All statistical analyses were conducted by use of SAS version
6.10.38 Characteristics of the patients and
control subjects were evaluated with Student's t test for
the continuous variables and 
2 test for
the categorical variables. The skewed distributions of VCAM-1,
E-selectin, and ICAM-1 were compared between patients and control
subjects by the Wilcoxon rank-sum test.39
Relationships between the adhesion molecules and potential CHD risk
factors were evaluated with Spearman's rank correlation coefficients
for the continuous variables and with the Wilcoxon rank-sum
test for the categorical variables. Unconditional logistic
regression analysis was used to determine the odds of incident
CHD in the follow-up study or the odds of CAA in the cross-sectional
study.40 Because of their use in the selection of
control subjects for matching to the CAA patients, all regression
analyses were adjusted for the concomitant effects of race,
age, and sex. Initially, regression analyses were conducted to
identify the odds of disease risk for each SD change of the adhesion
molecules. To further identify whether the associations between the
adhesion molecules and disease are the same across the range of values,
logistic regression analyses were conducted if levels of the
adhesion molecules were considered as categorical variables defined
by quartiles of their race-specific distributions. We then tested for a
threshold effect by testing for departures from linearity using a
restricted cubic spline model.41 A value of
P<.05 was considered statistically significant for all
analyses.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The sample of 792 ARIC participants includes 204 incident CHD patients (33 blacks and 171 whites), 272 CAA patients (44 blacks and 228 whites), and 316 control subjects (72 blacks and 244 whites). For CHD and CAA patients, levels of total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, fibrinogen, the atherogenic potential of the diet (Keys score),42 and white blood cell count were significantly higher than those for control subjects in whites. For both CHD and CAA patients, frequencies of hypertension (43% in CHD, 37% in CAA) and diabetes mellitus (22% for CHD patients, 12% for CAA patients) were significantly higher than those for control subjects (hypertension, 19%; diabetes mellitus, 3%). Plasma HDL cholesterol levels were significantly lower in the incident CHD patients (mean, 1.07 mmol/L) than in the CAA patients (mean, 1.12 mmol/L), but the levels of plasma LDL cholesterol or triglycerides were not significantly different. The frequency of diabetic patients was significantly higher for CHD patients than for CAA patients. In blacks, the differences between patients and control subjects were consistent with those observed in whites, but because of the smaller number of subjects, the difference did not always reach statistical significance.
Means and SDs of VCAM-1 were not statistically different among the CHD
patients, CAA patients, and control subjects (Table 1
). Consistent associations of
levels of E-selectin and ICAM-1 with CHD and CAA were observed in
whites and blacks. In whites, average E-selectin levels were
significantly higher in incident CHD patients (38.4 ng/mL) and CAA
patients (41.5 ng/mL) than in the control group (32.8 ng/mL). Likewise,
for ICAM-1, the CHD patients (288.7 ng/mL) and the CAA patients (283.6
ng/mL) had significantly higher levels than the control subjects (244.2
ng/mL). There was no significant difference in E-selectin or ICAM-1
levels between the CHD and the CAA patients. In blacks, significantly
elevated E-selectin levels were observed in both the incident CHD and
CAA patient groups compared with the control subjects. For ICAM-1,
elevated levels were observed in both patient groups. When only the
control subjects were considered, levels of VCAM-1 and ICAM-1 were
significantly lower in blacks than in whites.
|
Among the control subjects, the correlation between levels of
E-selectin and ICAM-1 was r=.22 (P=.0001);
between VCAM-1 and ICAM-1, r=.17 (P=.004); and
between VCAM-1 and E-selectin, r=.006 (P=.92).
VCAM-1 levels were significantly correlated with age, von
Willebrand factor, and white blood cell count (Table 2). E-selectin level was positively
correlated with body mass index, triglyceride, fibrinogen,
and white blood cell count and was negatively correlated with HDL
cholesterol. ICAM-1 level was positively correlated with
cigarette-years for smokers and white blood cell count. Levels of
VCAM-1 were significantly higher for those with diabetes than for
nondiabetics (Table 3). For E-selectin,
subjects with hypertension had significantly higher levels than their
normotensive counterparts. Levels of E-selectin were significantly
higher in subjects with diabetes than in nondiabetics. Women had higher
levels of ICAM-1 than men. Levels of ICAM-1 were significantly higher
for those with diabetes. For those who had smoked or still smoked
cigarettes, levels of ICAM-1 were significantly higher than those who
never smoked.
|
|
Table 4 shows the results of logistic
regression analyses predicting the risk of incident CHD and the
probabilities of being a CAA patient. There was no significant
relationship between VCAM-1 and CHD or CAA. E-selectin was
significantly associated with incident CHD (OR, 1.54; 95% CI,
1.27–1.86). However, this association was not significant after
adjustment for effects of established CHD risk factor variables
(age, sex, body mass index, total cholesterol, HDL
cholesterol, cigarette-years for smokers, hypertension, and
diabetes) and factors related to levels of the adhesion molecules
(triglyceride, fibrinogen, von Willebrand factor,
and white blood cell count).43 The level of
ICAM-1 was a significant predictor of incident CHD in all models. The
odds of incident CHD in the fully adjusted model increased by 1.88 for
each SD increase in ICAM-1 level. The relationship between level of
E-selectin and the occurrence of CAA was significant in all models (OR,
1.36; 95% CI, 1.09–1.70). The association between levels of ICAM-1
and CAA was also statistically significant in all models (OR, 1.34;
95% CI, 1.07–1.68).
|
To evaluate whether the associations between plasma levels of
E-selectin, ICAM-1, and disease were present across the range of
values or were restricted to those with high levels, subjects were
grouped by race-specific quartiles and the analyses were
repeated with the corresponding categorical variables. Table 5 shows the odds of incident CHD or the
occurrence of CAA for those with levels of E-selectin and ICAM-1 in the
second, third, and fourth quartiles compared with those with levels in
the first quartile. These data indicate that the risk of developing CHD
was highest in those with E-selectin and ICAM-1 levels in the highest
quartile. The risk of incident CHD for those with E-selectin in the
fourth quartile was significantly elevated (OR, 2.98; 95% CI,
1.74–5.10). The association between E-selectin and incident CHD was
not significant after the effects of a set of established risk factors
and factors related to levels of the circulating adhesion molecules
were considered. In contrast, after the effects of the established risk
factors and those variables related to adhesion molecule levels
were considered, the odds of developing clinical CHD for those in the
upper quartile of the ICAM-1 distribution was 5.53 times (95% CI,
2.51–12.21) higher than those in the lowest quartile. Elevated levels
of E-selectin were significantly associated with the occurrence of CAA
in the models adjusted for well-established CHD risk factors and
variables related to adhesion molecule levels. Individuals with CAA
were 2.03 times (95% CI, 1.14–3.62) more likely to be in the highest
quartile of E-selectin distribution at the baseline examination
compared with the control groups. For ICAM-1, the odds of being a CAA
case for those in the upper quartile of the ICAM-1 distribution were
2.64 (95% CI, 1.40–5.01) times higher than those in the lowest
quartile after the effects of established risk factors and those
variables related to adhesion molecule levels were considered.
However, a formal statistical test (see "Methods") did not indicate
a statistically significant threshold effect for ICAM-1 in predicting
incident CHD or the occurrence of CAA.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Our results showed that levels of circulating ICAM-1 predict CAA and incident CHD and that this relationship cannot be accounted for by the confounding effects of other CHD risk factors. The results also demonstrated a significant association between levels of circulating E-selectin and occurrence of CAA. A significant association between circulating ICAM-1, E-selectin, and sequelae of atherosclerosis has been reported in previous studies.44,45 Blann and McCollum44 reported significantly higher values of circulating ICAM-1 in patients with peripheral vascular disease and ischemic heart disease than in healthy control subjects. Squadrito et al45 reported significantly higher levels of circulating ICAM-1 and E-selectin in patients with acute myocardial infarction than in patients with chronic stable angina and healthy control subjects. The present study is the first one to comprehensively examine the ability of circulating VCAM-1, E-selectin, and ICAM-1 to predict incident CHD. This is also the first study to evaluate the relationship between circulating adhesion molecules and atherosclerosis and CHD in both blacks and whites. However, the number of black incident CHD patients is relatively small, so prudence is necessary in interpretation of their results.
On the basis of the "response to injury" hypothesis, atherosclerosis parallels the inflammatory process, and one of the earliest events in both is the adhesion of circulating monocytes to intact endothelial cells.46,47 Local accumulation of leukocytes in the vascular wall includes initial marginalization and rolling of the leukocytes along the endothelium, a process mediated by the selectins, then attachment to endothelial cells and transmigration into the intimal spaces, a process mediated by the adhesive molecules expressed by activated endothelium.14 VCAM-1, E-selectin, and ICAM-1 have been consistently observed within the milieu of the atherosclerotic plaque. Although the presence of ICAM-1 has been observed on normal arterial endothelium, consistent and strong expression of ICAM-1 has been associated with atherosclerotic lesions.23,25 Focal expression of endothelium-specific E-selectin on atherosclerotic lesions has also been reported consistently. Despite the large body of literature on the expression and function of the cellular adhesion molecules, the biological properties and function of the circulating form of these molecules remain unclear. Therefore, any discussion of the potential mechanisms relating circulating adhesion molecule levels to CAA and incident CHD is necessarily speculative. There is a large body of literature documenting an association between plasma levels of the circulating adhesion molecules and the occurrence of chronic inflammatory diseases.15
We report here the distributions of circulating VCAM-1, E-selectin, and ICAM-1 for CAA and incident CHD patients and control subjects in the ARIC study and evaluate their relationship with long-standing risk factors (eg, total cholesterol). The observed relationships were, in general, consistent with data from both in vivo and in vitro experimental studies. Cockerill et al48 reported decreased expression of VCAM-1, E-selectin, and ICAM-1 on endothelial cell cultures that were exposed to isolated HDL particles. A previous study also showed increased levels of soluble ICAM-1 in patients with marked elevation of triglycerides and low HDL cholesterol.49 In the present study, levels of E-selectin were significantly correlated with HDL cholesterol in the control group. Significantly higher levels of the adhesion molecules were observed for those diagnosed with diabetes, which is consistent with previous studies showing elevated levels of E-selectin and ICAM-1 in diabetic patients.50,51 It is unknown whether this association is the consequence of accompanying atherosclerosis or whether there is a direct effect of hyperglycemia/hyperinsulinemia on the expression of the adhesion molecules, which has been demonstrated in experimental rabbits.52 We observed significantly higher levels of ICAM-1 for smokers than for nonsmokers as well as significant correlation between ICAM-1 and cigarette-years for smokers, and a positive relationship has been observed in an in vitro study. Kalra et al53 reported that cigarette smoke condensate induced ICAM-1 expression in cultured human umbilical vein cells and hypothesized a direct effect of cigarette smoking in stimulating ICAM-1 expression. We evaluated the relationship of ICAM-1 with incident CHD and CAA in multivariate logistic regression models and showed that the association between ICAM-1 level and CHD and CAA were independent of well-accepted risk factors and factors correlated with circulating VCAM-1, E-selectin, and ICAM-1 levels.
The level of E-selectin was positively related to the degree of
atherosclerotic burden, as measured by carotid artery wall thickness,
but was not a significant predictor of clinical CHD after
multivariate analysis, as shown in Tables 4
and 5. In light of the known function of E-selectin in the initial
margination and rolling of leukocytes along the vascular
endothelium,20 the association of
E-selectin with CAA but not CHD indicates that E-selectin might be
involved in the early steps of atherosclerosis. In
contrast, there was a consistent relationship between the
levels of circulating ICAM-1 and both incident CHD and CAA. One
possible explanation for these data is that levels of circulating
ICAM-1 are more closely related to the activity of
atherosclerosis. Increased levels of ICAM-1 may be
important in migration of increased numbers of T lymphocytes into
active lesions.54 Another possibility is that
patients with higher circulating levels of ICAM-1 have an increased
number of plaques prone to rupture, thrombi, or other events leading to
clinical CHD. The interaction between fibrinogen and ICAM-1 observed in
an in vitro study provides evidence suggesting an association between
ICAM-1 and thrombosis/ischemic events.55
Another explanation for these observations is that
atherosclerosis in different arterial beds
such as the carotid and coronary arteries may have differential
expression of cell adhesion molecules.
It is unknown why the level of circulating VCAM-1 was not associated with either CAA or CHD. Results of immunohistochemical studies have consistently shown much weaker VCAM-1 expression than those for E-selectin and ICAM-1.23,25,26 VCAM-1 is different from ICAM-1 with respect to the ligand it binds to, the time duration of its expression, and the cell and tissue type in which it is expressed.56 In an animal model, Walpola et al57 observed upregulation of VCAM-1 and downregulation of ICAM-1 by low shear stress and upregulation of both VCAM-1 and ICAM-1 by high shear stress. The accumulated data imply that VCAM-1 may play an important role in early atherogenesis but a less important role in advanced, complex lesions. However, further studies are clearly necessary.
In summary, we have defined significant relationships of circulating E-selectin and ICAM-1 levels with the burden of atherosclerosis, as measured by carotid B-mode ultrasound, and CHD, as measured by the number of incident patients in the ARIC study. The results of this study bode well for the utility of the circulating adhesion molecules to serve as indicators of subclinical disease, although they do not directly indicate their use as such at this time. Clearly, more data are necessary on the validity of their use as molecular markers of atherosclerosis and comparison with other tests, both invasive and noninvasive. The present study has the limitation of recruiting control subjects with thin carotid arterial walls; therefore, the odds ratios for incident CHD patients reported here are most likely overestimates of those estimated from a random sample from the general population.58 However, it is worth pointing out that average VCAM-1, E-selectin, and ICAM-1 levels for the ARIC thin-wall control subjects were not different from those reported from other control groups.59–61 The data presented here should provide an impetus for further studies defining the utility of plasma measures of these adhesion molecules to predict plaque progression, regression, and CHD. The availability of a molecular marker for preclinical atherosclerosis will facilitate diagnosis and more-directed intervention strategies targeted at those at increased risk.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported by contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022 from the National Heart, Lung, and Blood Institute. We thank Myra Carpenter and Charmaine Marquis (University of Carolina, Chapel Hill, Coordinating Center) for statistical assistance. We are indebted to ARIC investigators Phyllis Johnson, Marilyn Knowles, Catherine Paton (University of North Carolina, Chapel Hill); Dawn Scott, Nadine Shelton, Carol Smith, Pamela Williams (University of North Carolina, Forsyth County); Betty Warren, Dorothy Washington, Mattye Watson, Nancy Wilson (University of Mississippi Medical Center, Jackson); Margaret Skelton, Gina Tritle, Shirley VanPilsum, Lori Vitelli (University of Minnesota, Minneapolis); John Nelling, Rodney Palmer, Serena Bell, Joyce Chabot (Johns Hopkins University, Baltimore, Md); Valarie Stinson, Pam Pfile, Hogan Pham, Teri Trevino (University of Texas Medical School, Houston); Wanda R. Alexander, Doris J. Harper, Charles E. Rhodes, Selma M. Soyal (The Methodist Hospital, Atherosclerosis Clinical Laboratory, Houston); Linda Allred, Carolyn Bell, Nancy Bourne, Charlene Kearney-Cash (Bowman-Gray School of Medicine, Ultrasound Reading Center, Winston-Salem, NC); and Marston Youngblood, Ding-Yi Zhao, Paula Bell, and Hope Bryan (University of North Carolina, Chapel Hill, Coordinating Center).
|
Footnotes |
|---|
Guest editor for this article was Michael J. Davies, MD, St George's Hospital Medical School, London, UK.
Received May 16, 1997; revision received September 3, 1997; accepted September 12, 1997.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Nicholls ES, Peruga A, Restrepo HE. Cardiovascular disease mortality in the Americas. World Health Stat Q. 1993;46:134–150.[Medline] [Order article via Infotrieve]
2.
Faggiotto A, Ross R, Harker L. Studies of
hypercholesterolemia in the nonhuman primate,
I: change that leads to fatty streak formation.
Arteriosclerosis. 1990;4:323–340.
3.
Fowler S, Berberian PA, Shio H, Goldfischer S,
Wolinsky H. Characterization of cell populations isolated from aortas
of rhesus monkeys with experimental atherosclerosis.
Circ Res. 1980;46:520–553.
4. Gerrity RG. The role of the monocyte in atherogenesis, I; transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181–190.[Abstract]
5. Joris I, Zand T, Nunnari JJ, Krolikowski FJ, Majno G. Studies on the pathogenesis of atherosclerosis, I; adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol. 1983;113:341–358.[Abstract]
6. Munro JM, Cotran RS. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest. 1988;58:249–261.[Medline] [Order article via Infotrieve]
7.
Brown BG, Gallery CA, Badger RS, Kennedy JW, Detlef M,
Bolson EL, Dodge HT. Incomplete lysis of thrombus in the moderate
underlying atherosclerotic lesion during intracoronary infusion
of streptokinase for acute myocardial infarction: quantitative
angiographic observations. Circulation. 1986;73:653–661.
8. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12:56–62.[Abstract]
9.
Gotto AM. Lipid lowering, regression, and
coronary events. Circulation. 1995;92:646–656.
10. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Garsiner J. Cost-effectiveness analysis in heart disease, II: preventive therapies. Prog Cardiovasc Dis. 1995;37:243–271.[Medline] [Order article via Infotrieve]
11.
Arad Y, Spadaro LA, Goodman K, Lledo-Perez A, Sherman
S, Lerner G, Guerci AD. Predictive value of electron beam computed
tomography of the coronary arteries: 19-month follow-up of 1173
asymptomatic subjects. Circulation. 1996;93:1951–1953.
12.
Patterson RE, Eisner RL, Horowitz SF. Comparison of
cost-effectiveness and utility of exercise ECG, single photo emission
computed tomography, positron emission tomography, and coronary
angiography for diagnosis of coronary artery disease.
Circulation. 1995;91:54–65.
13. Hajjar DP, Nicholson AC. Atherosclerosis. Am Sci. 1995;83:460–467.
14. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J. 1994;8:504–512.[Abstract]
15. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today. 1993;14:506–512.[Medline] [Order article via Infotrieve]
16. Tedder TS, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. FASEB J. 1995;9:866–873.[Abstract]
17.
Chen CC, Rosenbloom CL, Anderson DC, Manning AM.
Selective inhibition of E-selectin, vascular cell adhesion molecule-1,
and intercellular adhesion molecule-1 expression by
inhibitors of I
B-
phosphorylation. J Immunol. 1995;155:3538–3545.[Abstract]
18.
Collins T, Read MA, Neish AS, Whitley MZ, Thanos D,
Maniatis T. Transcriptional regulation of endothelial
cell adhesion molecules: NF-B and cytokine-inducible
enhancers. FASEB J. 1995;9:899–909.[Abstract]
19.
Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer
TA. Induction by IL 1 and interferon-
: tissue distribution,
biochemistry, and function of a natural adherence molecule (ICAM-1).
J Immunol. 1986;137:245–254.[Abstract]
20. Lasky LA. Selectin-carbohydrate interactions and the initiation of the inflammatory response. Ann Rev Biochem. 1995;64:113–139.[Medline] [Order article via Infotrieve]
21. Lawrence MB, Springer TA. Leukocyte roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991;65:859–873.[Medline] [Order article via Infotrieve]
22. Li H, Cybulsky MI, Gimbrone MA, Libby P. Inducible expression of vascular cell adhesion molecule-1 by vascular smooth muscle cells in vitro and within rabbit atheroma. Am J Pathol. 1993;143:1551–1559.[Abstract]
23. Davies MJ, Gordon JL, Gearing AJH, Pigott R, Woolf N, Katz D, Kyriakopoulos A. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol. 1993;171:223–229.[Medline] [Order article via Infotrieve]
24. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665–673.[Abstract]
25. van der Wal AC, Das PK, Tigges AJ, Becker AE. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol. 1992;141:1427–1433.[Abstract]
26. Wood KM, Cadogan MD, Ramshaw AL, Parums DV. The distribution of adhesion molecules in human atherosclerosis. Histopathology. 1993;22:437–444.[Medline] [Order article via Infotrieve]
27. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, Lobb R, Alpers CE. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest. 1993;92:945–951.
28.
O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE.
Neovascular expression of E-selectin, intercellular adhesion molecule-1
in human atherosclerosis and their relation to intimal
leukocyte content. Circulation. 1996;93:672–682.
29. Ballantyne CM, Mainolfi EA, Young JB, Windsor NT, Cocanougher B, Lawrence EC, Pollack MS, Entman ML, Rothlein R. Relationship of increased levels of circulating intercellular adhesion molecule 1 after heart transplantation to rejection: human leukocyte antigen mismatch and survival. J Heart Lung Transplant. 1994;13:597–603.[Medline] [Order article via Infotrieve]
30. Nakai K, Itoh C, Kawazoe K, Miura Y, Sotyanagi H, Hotta K, Itoh T, Kamata J, Hiramori K. Concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) correlated with expression of VCAM-1 mRNA in the human atherosclerotic aorta. Coron Artery Dis. 1996;6:497–502.
31. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol. 1991;147:3788–3793.[Abstract]
32. Pigott R, Dillon LP, Hemingway I, Gearing AJH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cell. Biochem Biophys Res Commun. 1992;187:584–589.[Medline] [Order article via Infotrieve]
33.
The ARIC Investigators. The
Atherosclerosis Risk In Communities (ARIC) study:
design and objectives. Am J Epidemiol. 1989;129:687–702.
34.
Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R.
Intimal plus medial thickness of arterial wall: a direct
measurement with ultrasound imaging. Circulation. 1986;74:1399–1406.
35.
Brown SA, Hutchinson R, Morrisett J, Boerwinkle E,
Davis CE, Gotto AM Jr, Patsch W. Plasma lipid, lipoprotein
cholesterol, and apolipoprotein distributions in selected
US communities: the Atherosclerosis Risk in Communities
(ARIC) study. Arterioscler Thromb. 1993;13:1139–1158.
36. Chambless LE, McMahon R, Wu KK, Folsom A, Finch A, Shen Y-L. Short-term intraindividual variability in hemostatic factors: the ARIC study. Ann Epidemiol. 1992;2:723–733.[Medline] [Order article via Infotrieve]
37.
Folsom AR, Wu KK, Shahar E, Davis CE. Association of
hemostatic variables with prevalent cardiovascular
disease and asymptomatic carotid artery
atherosclerosis. Arterioscler Thromb. 1993;13:1829–1836.
38. SAS Institute. SAS User's guide: Statistics. Cary, NC: SAS Institute Inc; 1994.
39. Conover WJ. Practical Nonparametric Statistics. 2nd ed. New York, NY: John Wiley & Sons Inc: 1980.
40. Cox DR, Snell EJ. The Analysis of Binary Data. 2nd ed. London, UK: Chapman and Hall; 1989.
41.
Harrell FE Jr, Lee KL, Pollock BG. Regression models in
clinical studies: determining relationships between predictors and
response. J Natl Cancer Inst. 1988;80:1198–1202.
42. Anderson JT, Jacobs DR, Foster N, Hall Y, Moss D, Mojonnier L, Blackburn H. Scoring systems for evaluating dietary pattern effect on serum cholesterol. Prev Med. 1979;8:525–537.[Medline] [Order article via Infotrieve]
43. Wilson PWF. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens. 1994;7:7S–12S.[Medline] [Order article via Infotrieve]
44. Blann AD, McCollum CN. Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost. 1994;72:151–154.[Medline] [Order article via Infotrieve]
45. Squadrito F, Saitta A, Altavilla D, Ioculano M, Canale P, Campo GM, Squadrito G, Di Tano G, Mazzu A, Caputi AP. Thrombolytic therapy with urokinase reduces increased circulating endothelial adhesion molecules in acute myocardial infarction. Inflamm Res. 1996;45:14–19.[Medline] [Order article via Infotrieve]
46. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]
47. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med. 1986;314:488–500.[Medline] [Order article via Infotrieve]
48.
Cockerill GW, Rye K-A, Gamble JR, Vadas MA, Barter PJ.
High-density lipoproteins inhibit cytokine-induced
expression of endothelial cell adhesion molecules.
Arterioscler Thromb Vasc Biol. 1995;15:1987–1994.
49.
Hackman A, Abe Y, Insull W, Pownall H, Smith L, Dunn K,
Gotto AM Jr, Ballantyne CM. Levels of soluble adhesion molecules in
patients with dyslipidemia. Circulation. 1996;93:1334–1338.
50. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb Haemost. 1994;72:979–984.[Medline] [Order article via Infotrieve]
51. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathologic significance. Ann N Y Acad Sci. 1992;667:324–331.[Medline] [Order article via Infotrieve]
52.
Richardson M, Hadcock SJ, DeReske M, Cybulsky MI.
Increased expression in vivo of VCAM-1 and E-selectin by the aortic
endothelium of normolipemic and hyperlipemic diabetic
rabbits. Arterioscler Thromb. 1994;14:760–769.
53. Kalra VK, Ying Y, Deemer K, Natarajan R, Nadler JL, Coates TD. Mechanism of cigarette smoke condensate induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol. 1994;160:154–162.[Medline] [Order article via Infotrieve]
54.
Zeiher AM, Goebel H, Schachinger V, Ihling C.
Tissue endothelial-1 immunoreactivity in the active coronary
atherosclerotic plaque: a clue to the mechanism of increased
vasoreactivity of the culprit lesion in unstable angina.
Circulation. 1995;91:941–947.
55.
Languino LR, Duperray A, Joganic KJ, Fornaro M,
Thornton GB, Altieri DC. Regulation of
leukocyte-endothelium interaction and leukocyte
transendothelial migration by intercellular adhesion
molecule 1-fibrinogen recognition. Proc Natl Acad Sci
U S A. 1995;92:1505–1509.
56.
Carlos TM, Schwartz BR, Kovach NL, Yee E, Rosso M,
Osborn L, Chi-Rosso G, Newman B, Lobb R, Harlan JM. Vascular cell
adhesion molecule-1 mediates lymphocyte adherence to
cytokine-activated cultured human
endothelial cells. Blood. 1990;76:965–970.
57.
Walpola PL, Gotlieb AI, Cybulsky MI, Langille BL.
Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries
exposed to altered shear stress. Arterioscler Thromb Vasc
Biol. 1995;15:2–10.
58. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984;40:63–75.[Medline] [Order article via Infotrieve]
59. Lampeter ER, Kishimoto TK, Rothlein R, Mainolfi EA, Bertrams J, Kolb H, Martin S. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes. 1992;41:1668–1671.[Abstract]
60. Kowalzick L, Kleinheinz A, Neuber K, Weichenthal M, Köhler I, Ring J. Elevated serum levels of soluble adhesion molecules ICAM-1 and ELAM-1 in patients with severe atopic eczema and influence of UVA1 treatment. Dermatology. 1995;190:14–18.[Medline] [Order article via Infotrieve]
61. Klein B, Levin I, Kfir B, Mishaeli M, Shapira J, Klein T. The significance of soluble interleukin-2, soluble interleukin-2 receptors, soluble ICAM-1 and ß2-microglobulin in breast cancer patients. Tumor Biol. 1995;16:290–296.
This article has been cited by other articles:
 |
|
 |
|
  A. D. Paterson, M. F. Lopes-Virella, D. Waggott, A. P. Boright, S. M. Hosseini, R. E. Carter, E. Shen, L. Mirea, B. Bharaj, L. Sun, et al. Genome-Wide Association Identifies the ABO Blood Group as a Major Locus Associated With Serum Levels of Soluble E-Selectin Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1958 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rohatgi, A. W. Owens, A. Khera, C. R. Ayers, K. Banks, S. R. Das, J. D. Berry, D. K. McGuire, and J. A. de Lemos Differential Associations Between Soluble Cellular Adhesion Molecules and Atherosclerosis in the Dallas Heart Study: A Distinct Role for Soluble Endothelial Cell-Selective Adhesion Molecule Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1684 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schmidt, J. Hulthe, and B. Fagerberg Baseline ICAM-1 and VCAM-1 Are Increased in Initially Healthy Middle-Aged Men Who Develop Cardiovascular Disease During 6.6 Years of Follow-Up Angiology, February 1, 2009; 60(1): 108 - 114. [Abstract] [PDF]
|
|
|
|
 |
|
 J. C. States, S. Srivastava, Y. Chen, and A. Barchowsky Arsenic and Cardiovascular Disease Toxicol. Sci., February 1, 2009; 107(2): 312 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Shaw, A. Bobik, A. Murphy, P. Kanellakis, P. Blombery, N. Mukhamedova, K. Woollard, S. Lyon, D. Sviridov, and A. M. Dart Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque Circ. Res., November 7, 2008; 103(10): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Khaleghi, Z. Ali, T. H. Mosley Jr., S. T. Turner, and I. J. Kullo Association of Soluble Cell Adhesion Molecules with Ankle-Brachial Index in a Biethnic Cohort of Predominantly Hypertensive Individuals Clin. Chem., November 1, 2008; 54(11): 1788 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. O'Brien, S. Ling, E. Abbas, A. Dai, J. Zhang, W. C. Wang, A. Bensoussan, R. Luo, Z.-X. Guo, and P. A. Komesaroff A Chinese Herbal Preparation Containing Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum Reduces Circulating Adhesion Molecules Evid. Based Complement. Altern. Med., September 27, 2008; (2008) nen060v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Musso, R. Gambino, S. Bo, B. Uberti, G. Biroli, G. Pagano, and M. Cassader Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome?: A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects Diabetes Care, March 1, 2008; 31(3): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Conen, B M Everett, R J Glynn, and P M Ridker Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial Heart, March 1, 2008; 94(3): e13 - e13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-J. Zhang, K. E. Bird, T. S. McMillen, R. C. LeBoeuf, T. M. Hagen, and B. Frei Dietary {alpha}-Lipoic Acid Supplementation Inhibits Atherosclerotic Lesion Development in Apolipoprotein E Deficient and Apolipoprotein E/Low-Density Lipoprotein Receptor Deficient Mice Circulation, January 22, 2008; 117(3): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Plat, A. Jellema, J. Ramakers, and R. P. Mensink Weight Loss, but Not Fish Oil Consumption, Improves Fasting and Postprandial Serum Lipids, Markers of Endothelial Function, and Inflammatory Signatures in Moderately Obese Men J. Nutr., December 1, 2007; 137(12): 2635 - 2640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Y.L. Zee, S. Cheng, H. A. Erlich, K. Lindpaintner, N. Rifai, J. E. Buring, and P. M Ridker Intercellular Adhesion Molecule 1 (ICAM1) Lys56Met and Gly241Arg Gene Variants, Plasma-Soluble ICAM1 Concentrations, and Risk of Incident Cardiovascular Events in 23 014 Initially Healthy White Women Stroke, December 1, 2007; 38(12): 3152 - 3157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nylaende, A.J. Kroese, B. Morken, E. Stranden, G. Sandbaek, A.K. Lindahl, H. Arnesen, and I. Seljeflot Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study Vascular Medicine, November 1, 2007; 12(4): 275 - 283. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Devaraj, A. T. Cheung, I. Jialal, S. C. Griffen, D. Nguyen, N. Glaser, and T. Aoki Evidence of Increased Inflammation and Microcirculatory Abnormalities in Patients With Type 1 Diabetes and Their Role in Microvascular Complications Diabetes, November 1, 2007; 56(11): 2790 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Hamilton, G. T Chew, and G. F Watts Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus Diabetes and Vascular Disease Research, June 1, 2007; 4(2): 89 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A Nettleton, L. M Steffen, M. B Schulze, N. S Jenny, R G. Barr, A. G Bertoni, and D. R Jacobs Jr Associations between markers of subclinical atherosclerosis and dietary patterns derived by principal components analysis and reduced rank regression in the Multi-Ethnic Study of Atherosclerosis (MESA) Am. J. Clinical Nutrition, June 1, 2007; 85(6): 1615 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lavi, A. Prasad, E. H. Yang, V. Mathew, R. D. Simari, C. S. Rihal, L. O. Lerman, and A. Lerman Smoking Is Associated With Epicardial Coronary Endothelial Dysfunction and Elevated White Blood Cell Count in Patients With Chest Pain and Early Coronary Artery Disease Circulation, May 22, 2007; 115(20): 2621 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barac, U. Campia, and J. A. Panza Methods for Evaluating Endothelial Function in Humans Hypertension, April 1, 2007; 49(4): 748 - 760. [Full Text] [PDF]
|
|
|
|
|
|
S. Kapiotis, G. Holzer, G. Schaller, M. Haumer, H. Widhalm, D. Weghuber, B. Jilma, G. Roggla, M. Wolzt, K. Widhalm, et al. A Proinflammatory State Is Detectable in Obese Children and Is Accompanied by Functional and Morphological Vascular Changes Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2541 - 2546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lopez-Garcia, R. M van Dam, L. Qi, and F. B Hu Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 888 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Folsom, L. E. Chambless, C. M. Ballantyne, J. Coresh, G. Heiss, K. K. Wu, E. Boerwinkle, T. H. Mosley Jr, P. Sorlie, G. Diao, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med, July 10, 2006; 166(13): 1368 - 1373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hong, R. A. Nelesen, P. L. Krohn, P. J. Mills, and J. E. Dimsdale The Association of Social Status and Blood Pressure With Markers of Vascular Inflammation Psychosom Med, July 1, 2006; 68(4): 517 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A Nettleton, L. M Steffen, E. J Mayer-Davis, N. S Jenny, R. Jiang, D. M Herrington, and D. R Jacobs Jr Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA) Am. J. Clinical Nutrition, June 1, 2006; 83(6): 1369 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hemelaar, P. Kenemans, C.G. Schalkwijk, D.D.M. Braat, and M.J. van der Mooren No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women Hum. Reprod., June 1, 2006; 21(6): 1635 - 1642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Devaraj, N. Glaser, S. Griffen, J. Wang-Polagruto, E. Miguelino, and I. Jialal Increased Monocytic Activity and Biomarkers of Inflammation in Patients With Type 1 Diabetes Diabetes, March 1, 2006; 55(3): 774 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. McCaffery, N. Frasure-Smith, M.-P. Dube, P. Theroux, G. A. Rouleau, Q. Duan, and F. Lesperance Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med, March 1, 2006; 68(2): 187 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Nylaende, A Kroese, E Stranden, B Morken, G Sandbaek, A. Lindahl, H Arnesen, and I Seljeflot Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease Vascular Medicine, February 1, 2006; 11(1): 21 - 28. [Abstract] [PDF]
|
|
|
|
|
|
G. Brevetti, V. Schiano, and M. Chiariello Cellular adhesion molecules and peripheral arterial disease Vascular Medicine, February 1, 2006; 11(1): 39 - 47. [Abstract] [PDF]
|
|
|
|
|
|
W. L Hall, K. Vafeiadou, J. Hallund, S. Bugel, C. Koebnick, M. Reimann, M. Ferrari, F. Branca, D. Talbot, T. Dadd, et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1260 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wildhirt, C. Schulze, N. Conrad, R. Bauernschmitt, R. Lange, and W. von Scheidt Persistently increased systemic, but not cardiac-specific, adhesion molecule expression and coronary endothelial dysfunction in human cardiac allografts J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 1175 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Knopman, T. H. Mosley, D. J. Catellier, A. R. Sharrett, and for the Atherosclerosis Risk in Communities (ARIC) Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort Neurology, September 27, 2005; 65(6): 876 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T Fung, M. L McCullough, P. Newby, J. E Manson, J. B Meigs, N. Rifai, W. C Willett, and F. B Hu Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction Am. J. Clinical Nutrition, July 1, 2005; 82(1): 163 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Markus, B. Hunt, K. Palmer, C. Enzinger, H. Schmidt, and R. Schmidt Markers of Endothelial and Hemostatic Activation and Progression of Cerebral White Matter Hyperintensities: Longitudinal Results of the Austrian Stroke Prevention Study Stroke, July 1, 2005; 36(7): 1410 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Seddon, S. George, B. Rosner, and N. Rifai Progression of Age-Related Macular Degeneration: Prospective Assessment of C-Reactive Protein, Interleukin 6, and Other Cardiovascular Biomarkers Arch Ophthalmol, June 1, 2005; 123(6): 774 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koga, S. Sugiyama, K. Kugiyama, K. Watanabe, H. Fukushima, T. Tanaka, T. Sakamoto, M. Yoshimura, H. Jinnouchi, and H. Ogawa Elevated Levels of VE-Cadherin-Positive Endothelial Microparticles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1622 - 1630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. van Eeden, A. Yeung, K. Quinlam, and J. C. Hogg Systemic Response to Ambient Particulate Matter: Relevance to Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Yadav, G Marracci, J Lovera, W Woodward, K Bogardus, W Marquardt, L Shinto, C Morris, and D Bourdette Lipoic acid in multiple sclerosis: a pilot study Multiple Sclerosis, April 1, 2005; 11(2): 159 - 165. [Abstract] [PDF]
|
|
|
|
|
|
S. H. Johnsen, E. Fosse, O. Joakimsen, E. B. Mathiesen, E. Stensland-Bugge, I. Njolstad, and E. Arnesen Monocyte Count Is a Predictor of Novel Plaque Formation: A 7-Year Follow-up Study of 2610 Persons Without Carotid Plaque at Baseline The Tromso Study Stroke, April 1, 2005; 36(4): 715 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
E. Lopez-Garcia, M. B. Schulze, J. B. Meigs, J. E. Manson, N. Rifai, M. J. Stampfer, W. C. Willett, and F. B. Hu Consumption of Trans Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Dysfunction J. Nutr., March 1, 2005; 135(3): 562 - 566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui The role of inflammation in atherothrombosis: implications for clinical practice Vascular Medicine, February 1, 2005; 10(1): 45 - 53. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Vazquez, F. Pazos, J. R. Berrazueta, C. Fernandez-Escalante, M. T. Garcia-Unzueta, J. Freijanes, and J. A. Amado Effects of Changes in Body Weight and Insulin Resistance on Inflammation and Endothelial Function in Morbid Obesity after Bariatric Surgery J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 316 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. C. Grooteman and M. J. Nube Impact of the type of dialyser on the clinical outcome in chronic haemodialysis patients: does it really matter? Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2965 - 2970. [Full Text] [PDF]
|
|
|
|
|
|
A. R. Folsom, G. W. Evans, J. J. Carr, A. E. Stillman, and Atherosclerosis Risk in Communities (ARIC) Study I Association of Traditional and Nontraditional Cardiovascular Risk Factors with Coronary Artery Calcification Angiology, November 1, 2004; 55(6): 613 - 623. [Abstract] [PDF]
|
|
|
|
|
|
J. Okapcova and D. Gabor The Levels of Soluble Adhesion Molecules in Diabetic and Nondiabetic Patients with Combined Hyperlipoproteinemia and the Effect of Ciprofibrate Therapy Angiology, November 1, 2004; 55(6): 629 - 639. [Abstract] [PDF]
|
|
|
|
|
|
T. C. Register, K. P. Burdon, L. Lenchik, D. W. Bowden, G. A. Hawkins, B. J. Nicklas, K. Lohman, F.-C. Hsu, C. D. Langefeld, and J. J. Carr Variability of Serum Soluble Intercellular Adhesion Molecule-1 Measurements Attributable to a Common Polymorphism Clin. Chem., November 1, 2004; 50(11): 2185 - 2187. [Full Text] [PDF]
|
|
|
|
|
|
T. J. DeGraba Immunogenetic Susceptibility of Atherosclerotic Stroke: Implications on Current and Future Treatment of Vascular Inflammation Stroke, November 1, 2004; 35(11_suppl_1): 2712 - 2719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Barter, S. Nicholls, K.-A. Rye, G.M. Anantharamaiah, M. Navab, and A. M. Fogelman Antiinflammatory Properties of HDL Circ. Res., October 15, 2004; 95(8): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Lopez-Garcia, M. B Schulze, T. T Fung, J. B Meigs, N. Rifai, J. E Manson, and F. B Hu Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction Am. J. Clinical Nutrition, October 1, 2004; 80(4): 1029 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Zouridakis, P. Avanzas, R. Arroyo-Espliguero, S. Fredericks, and J. C. Kaski Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris Circulation, September 28, 2004; 110(13): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Chilton Pathophysiology of Coronary Heart Disease: A Brief Review J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 5S - 8S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Caballero, A. Delgado, C. A. Aguilar-Salinas, A. N. Herrera, J. L. Castillo, T. Cabrera, F. J. Gomez-Perez, and J. A. Rull The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3943 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Keaney Jr, J. M. Massaro, M. G. Larson, R. S. Vasan, P. W. F. Wilson, I. Lipinska, D. Corey, P. Sutherland, J. A. Vita, and E. J. Benjamin Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study J. Am. Coll. Cardiol., July 7, 2004; 44(1): 168 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Cavusoglu, B. Timuralp, T. Us, Y. Akgun, G. Kudaiberdieva, B. Gorenek, A. Unalir, O. Goktekin, and N. Ata Cigarette Smoking Increases Plasma Concentrations of Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Angiology, July 1, 2004; 55(4): 397 - 402. [Abstract] [PDF]
|
|
|
|
|
|
E. Lopez-Garcia, M. B. Schulze, J. E. Manson, J. B. Meigs, C. M. Albert, N. Rifai, W. C. Willett, and F. B. Hu Consumption of (n-3) Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Activation in Women J. Nutr., July 1, 2004; 134(7): 1806 - 1811. [Abstract] [Full Text]
|
|
|
|
|
|
D. J Baer, J. T Judd, B. A Clevidence, and R. P Tracy Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study Am. J. Clinical Nutrition, June 1, 2004; 79(6): 969 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Meigs, F. B. Hu, N. Rifai, and J. E. Manson Biomarkers of Endothelial Dysfunction and Risk of Type 2 Diabetes Mellitus JAMA, April 28, 2004; 291(16): 1978 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Kaysen and J. P. Eiserich The Role of Oxidative Stress-Altered Lipoprotein Structure and Function and Microinflammation on Cardiovascular Risk in Patients with Minor Renal Dysfunction J. Am. Soc. Nephrol., March 1, 2004; 15(3): 538 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Wakatsuki, N. Ikenoue, K. Shinohara, K. Watanabe, and T. Fukaya Effect of Lower Dosage of Oral Conjugated Equine Estrogen on Inflammatory Markers and Endothelial Function in Healthy Postmenopausal Women Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 571 - 576. [Abstract] [Full Text]
|
|
|
|
|
|
P. Lind, G. Engstrom, L. Stavenow, L. Janzon, F. Lindgarde, and B. Hedblad Risk of Myocardial Infarction and Stroke in Smokers Is Related to Plasma Levels of Inflammation-Sensitive Proteins Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, R. C. Hoogeveen, H. Bang, J. Coresh, A. R. Folsom, G. Heiss, and A. R. Sharrett Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study Circulation, February 24, 2004; 109(7): 837 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nikander, M. Metsa-Heikkila, A. Tiitinen, and O. Ylikorkala Evidence of a Lack of Effect of a Phytoestrogen Regimen on the Levels of C-Reactive Protein, E-Selectin, and Nitrate in Postmenopausal Women J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5180 - 5185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Naghavi, P. Libby, E. Falk, S. W. Casscells, S. Litovsky, J. Rumberger, J. J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, et al. From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies: Part II Circulation, October 14, 2003; 108(15): 1772 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Hu and M. J. Stampfer Is Type 2 Diabetes Mellitus a Vascular Condition? Arterioscler Thromb Vasc Biol, October 1, 2003; 23(10): 1715 - 1716. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Miller, Y.-F. Chen, D. Xing, W. Feng, and S. Oparil Hormone Replacement Therapy and Inflammation: Interactions in Cardiovascular Disease Hypertension, October 1, 2003; 42(4): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ponthieux, B. Herbeth, S. Droesch, D. Lambert, and S. Visvikis Age- and Sex-related Reference Values for Serum Adhesion Molecule Concentrations in Healthy Individuals: Intercellular Adhesion Molecule-1 and E-, P-, and L-Selectin Clin. Chem., September 1, 2003; 49(9): 1544 - 1546. [Full Text] [PDF]
|
|
|
|
|
|
P. Cherian, G. J. Hankey, J. W. Eikelboom, J. Thom, R. I. Baker, A. McQuillan, J. Staton, and Q. Yi Endothelial and Platelet Activation in Acute Ischemic Stroke and Its Etiological Subtypes Stroke, September 1, 2003; 34(9): 2132 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Cao, C. Thach, T. A. Manolio, B. M. Psaty, L. H. Kuller, P. H.M. Chaves, J. F. Polak, K. Sutton-Tyrrell, D. M. Herrington, T. R. Price, et al. C-Reactive Protein, Carotid Intima-Media Thickness, and Incidence of Ischemic Stroke in the Elderly: The Cardiovascular Health Study Circulation, July 15, 2003; 108(2): 166 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Frazier Novel Predictors of Acute Coronary Syndrome Outcomes Biol Res Nurs, July 1, 2003; 5(1): 30 - 36. [Abstract] [PDF]
|
|
|
|
|
|
N. Sattar, J. Ramsay, L. Crawford, H. Cheyne, and I. A. Greer Classic and Novel Risk Factor Parameters in Women With a History of Preeclampsia Hypertension, July 1, 2003; 42(1): 39 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nuotio, P. J. Lindsberg, O. Carpen, L. Soinne, E. M.P. Lehtonen-Smeds, E. Saimanen, R. Lassila, T. Sairanen, S. Sarna, O. Salonen, et al. Adhesion molecule expression in symptomatic and asymptomatic carotid stenosis Neurology, June 24, 2003; 60(12): 1890 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Maurus, D. Schmidt, M. K.J. Schneider, M. I. Turina, J. D. Seebach, and G. Zund Hypoxia and reoxygenation do not upregulate adhesion molecules and natural killer cell adhesion on human endothelial cells in vitro Eur. J. Cardiothorac. Surg., June 1, 2003; 23(6): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Wu, N. Aleksic, C. M. Ballantyne, C. Ahn, H. Juneja, and E. Boerwinkle Interaction Between Soluble Thrombomodulin and Intercellular Adhesion Molecule-1 in Predicting Risk of Coronary Heart Disease Circulation, April 8, 2003; 107(13): 1729 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Signorelli, M. C. Mazzarino, L. D. Pino, G. Malaponte, C. Porto, G. Pennisi, G. Marchese, M. P. Costa, D. Digrandi, G. Celotta, et al. High circulating levels of cytokines (IL-6 and TNFa), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test Vascular Medicine, February 1, 2003; 8(1): 15 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Hassan, B. J. Hunt, M. O'Sullivan, K. Parmar, J. M. Bamford, D. Briley, M. M. Brown, D. J. Thomas, and H. S. Markus Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis Brain, February 1, 2003; 126(2): 424 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Shlipak, L. F. Fried, C. Crump, A. J. Bleyer, T. A. Manolio, R. P. Tracy, C. D. Furberg, and B. M. Psaty Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency Circulation, January 7, 2003; 107(1): 87 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Papagianni, M. Kalovoulos, D. Kirmizis, A. Vainas, A.-M. Belechri, E. Alexopoulos, and D. Memmos Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients Nephrol. Dial. Transplant., January 1, 2003; 18(1): 113 - 119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N.T. Mulvihill, B. Foley, P. Crean, and M. Walsh Prediction of cardiovascular risk using soluble cell adhesion molecules Eur. Heart J., October 2, 2002; 23(20): 1569 - 1574. [Full Text] [PDF]
|
|
|
|
|
|
S. Cuomo, P. Guarini, G. Gaeta, M. de Michele, F. Boeri, J. Dorn, M.G. Bond, and M. Trevisan Increased carotid intima-media thickness in children-adolescents, and young adults with a parental history of premature myocardial infarction Eur. Heart J., September 1, 2002; 23(17): 1345 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tanne, M. Haim, V. Boyko, U. Goldbourt, T. Reshef, S. Matetzky, Y. Adler, Y. A. Mekori, and S. Behar Soluble Intercellular Adhesion Molecule-1 and Risk of Future Ischemic Stroke: A Nested Case-Control Study From the Bezafibrate Infarction Prevention (BIP) Study Cohort Stroke, September 1, 2002; 33(9): 2182 - 2186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.S. Celermajer Understanding the pathophysiology of the arterial wall: which method should we choose? Eur. Heart J. Suppl., September 1, 2002; 4(suppl_F): F24 - F28. [Abstract] [PDF]
|
|
|
|
 |
|
 K. K. Koh Effects of estrogen on the vascular wall: vasomotor function and inflammation Cardiovasc Res, September 1, 2002; 55(4): 714 - 726. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne and M. L. Entman Soluble Adhesion Molecules and the Search for Biomarkers for Atherosclerosis Circulation, August 13, 2002; 106(7): 766 - 767. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Pradhan, N. Rifai, and P. M. Ridker Soluble Intercellular Adhesion Molecule-1, Soluble Vascular Adhesion Molecule-1, and the Development of Symptomatic Peripheral Arterial Disease in Men Circulation, August 13, 2002; 106(7): 820 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Jarvisalo, A. Harmoinen, M. Hakanen, U. Paakkunainen, J. Viikari, J. Hartiala, T. Lehtimaki, O. Simell, and O. T. Raitakari Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1323 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Sardo, M. Castaldo, M. Cinquegrani, M. Bonaiuto, A. Maesano, A. Versace, M. Spadaro, S. Campo, G. Nicocia, D. Altavilla, et al. Effects of Atorvastatin Treatment on sICAM-1 and Plasma Nitric Oxide Levels in Hypercholesterolemic Subjects Clinical and Applied Thrombosis/Hemostasis, July 1, 2002; 8(3): 257 - 263. [Abstract] [PDF]
|
|
|
|
|
|
K. Kohara, Y. Tabara, Y. Yamamoto, M. Igase, and T. Miki Chlamydia pneumoniae Seropositivity Is Associated With Increased Plasma Levels of Soluble Cellular Adhesion Molecules in Community-Dwelling Subjects: The Shimanami Health Promoting Program (J-SHIPP) Study Stroke, June 1, 2002; 33(6): 1474 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. van der Meer, M. P.M. de Maat, M. L. Bots, M. M.B. Breteler, J. Meijer, A. J. Kiliaan, A. Hofman, and J. C.M. Witteman Inflammatory Mediators and Cell Adhesion Molecules as Indicators of Severity of Atherosclerosis: The Rotterdam Study Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 838 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Haim, D. Tanne, V. Boyko, T. Reshef, U. Goldbourt, J. Leor, Y. A. Mekori, and S. Behar Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease: Data from the Bezafibrate Infarction Prevention (BIP) Study J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1133 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Calabresi, M. Gomaraschi, B. Villa, L. Omoboni, C. Dmitrieff, and G. Franceschini Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-Cholesterol Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 656 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Libby, P. M. Ridker, and A. Maseri Inflammation and Atherosclerosis Circulation, March 5, 2002; 105(9): 1135 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Glurich, S. Grossi, B. Albini, A. Ho, R. Shah, M. Zeid, H. Baumann, R. J. Genco, and E. De Nardin Systemic Inflammation in Cardiovascular and Periodontal Disease: Comparative Study Clin. Vaccine Immunol., March 1, 2002; 9(2): 425 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.J. Blake and P.M. Ridker Tumour necrosis factor-{alpha}, inflammatory biomarkers, and atherogenesis Eur. Heart J., March 1, 2002; 23(5): 345 - 347. [Full Text] [PDF]
|
|
|
|
|
|
T. Skoog, W. Dichtl, S. Boquist, C. Skoglund-Andersson, F. Karpe, R. Tang, M.G. Bond, U. de Faire, J. Nilsson, P. Eriksson, et al. Plasma tumour necrosis factor-{alpha} and early carotid atherosclerosis in healthy middle-aged men Eur. Heart J., March 1, 2002; 23(5): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Papayianni, E. Alexopoulos, P. Giamalis, L. Gionanlis, A.-M. Belechri, P. Koukoudis, and D. Memmos Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events Nephrol. Dial. Transplant., March 1, 2002; 17(3): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||